Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Johnson & Johnson Submits Covid-19 Vaccine Data To World Health Organization For Emergency Use Listing

By John F. Heerdink, Jr.

As per reports, Johnson & Johnson (JNJ) has submitted data to the World Health Organization (WHO) for emergency use listing of its single-dose COVID-19 vaccine, allowing wider access.

The healthcare giant informed that an emergency use listing is mandatory for supplying vaccines to the COVAX vaccine program, which is co-led by WHO and is working to deliver vaccine doses to middle-income countries and the poor. J&J entered into an agreement in December in support of the COVAX program. J&J’s vaccine can be stored at normal fridge temperatures, which is its unique selling point for countries with weaker healthcare facilities and infrastructure.

The company informed last month the vaccine was 66% effective in preventing COVID-19 in a large late-stage global trial against multiple variants of the coronavirus. The protection level of the vaccine varied from 72% in the United States, 57% in South Africa, and 66% in Latin America. Johnson & Johnson informed that the data delivered to WHO includes results from the late-stage trial.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

(Read Original Story: J&J applies to WHO for emergency use listing of COVID-19 vaccine in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us